Thu, Mar 5, 2015, 4:20 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

eResearchTechnology, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • barnstormer60 barnstormer60 Apr 24, 2005 12:16 AM Flag

    Why ERES has fallen and can't get up

    Following was included in his hotline dated today.

    I received a subscriber question from Ed about eResearch Technology (NASDAQ: ERES) about a paper regarding the draft regulations for QT trials to be considered at the ICH meeting in mid-May. Ed, I bought the paper for $50. All he is saying is that in addition to the QT studies there are other studies that should be done to confirm or not miss a real problem. I don't see how this would affect eResearch Technology significantly.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • There seems to be one potassium channel in particular that a drug could interfere with to cause prolonged QT in human heart cells. Among the non clinical studies that could be done first include studying the effect of the drug on individual heart cells or studying the effect of the drug in rabbits or dogs first. If these studies were non concerning, then clinical trials in humans would still have to be done later in the process.
      It may be that clinical trials in humans would not be done as the first studies to identify prolongation of the QT interval. This would have some negative impact on revenue for ERES but to what extent, I don't know. Clinical trials definiteley would not be going away. I can't imagine, nor have I seen, anyone proposing this.


Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.